Health Care Reform: Expansion of Medicare benefits to include prescription drugs, June 22, 1993 ; Health care service delivery infrastructure in inner-city and rural communities, June 24, 1993 ; Implementation of a national health budget, July 13, 1993U.S. Government Printing Office, 1993 |
No grāmatas satura
1.5. rezultāts no 59.
. lappuse
... Therapy Association , statement 326 Chicago Department of Health , Sheila Lyne , statement 330 Congressional Rural Caucus , Hon . Jill Long , Chair , and a Representative in Congress from the State of Indiana , statement 335 National ...
... Therapy Association , statement 326 Chicago Department of Health , Sheila Lyne , statement 330 Congressional Rural Caucus , Hon . Jill Long , Chair , and a Representative in Congress from the State of Indiana , statement 335 National ...
10. lappuse
... therapy problems before each prescription is filled and counseling offered by pharmacies , which must make ... therapeutic. criteria. ,. usually. on. a. monthly basis . All States send letters to physicians to 10.
... therapy problems before each prescription is filled and counseling offered by pharmacies , which must make ... therapeutic. criteria. ,. usually. on. a. monthly basis . All States send letters to physicians to 10.
12. lappuse
... therapeutic criteria , and appropriate interventions . Importantly , States are actively establishing electronic drug claims processing systems which will be capable of prospective drug utilization review . In addition , these ...
... therapeutic criteria , and appropriate interventions . Importantly , States are actively establishing electronic drug claims processing systems which will be capable of prospective drug utilization review . In addition , these ...
27. lappuse
... therapeutic drugs . I have a list showing the cost in the United States versus the cost in European countries , and Japan . It is on five of them , which are 75 - percent of the biotechnology therapeutic drug sales , one controlled by ...
... therapeutic drugs . I have a list showing the cost in the United States versus the cost in European countries , and Japan . It is on five of them , which are 75 - percent of the biotechnology therapeutic drug sales , one controlled by ...
28. lappuse
... therapeutic drug sales in the U.S. NOTE : Prices are at manufacturer , or wholesale , level , but are consistent for each product . The " mark - up " to consumers varies widely and the manfacturer has no control over the final price ...
... therapeutic drug sales in the U.S. NOTE : Prices are at manufacturer , or wholesale , level , but are consistent for each product . The " mark - up " to consumers varies widely and the manfacturer has no control over the final price ...
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
AARP ALTMAN Americans Association average beneficiaries billion BREWSTER Chairman STARK clinics Coalition Committee community health centers Cook County Hospital cost containment delivery system drug prices drug utilization review effective expenditure limits facilities Federal financing formularies funding global budget going Greene County gross domestic product growth health care delivery health care reform health care services health care system health services HMOs implementation incentives increase industry infrastructure inner city inner-city inpatient issues look managed care managed competition manufacturers MCSTEEN Medicaid Medicare MOSSINGHOFF national health networks nursing osteopathic outpatient patients payers payment percent Pete Stark pharmaceutical pharmacists physical therapists physicians policies population practitioners prescription drug benefit problems Puerto Ricans rebate reimbursement residents rural areas rural communities rural health safety net hospitals savings spending statement talking target testimony Thank therapy Todd Linden underserved uninsured urban VLADECK
Populāri fragmenti
3. lappuse - ... pages. 2. Copies of whole documents submitted as exhibit material will not be accepted for printing Instead. exhibit material should be referenced and quoted or paraphrased. All exhibit material not meeting these specifications will be maintained in the Committee files for review and use by the Committee. 3. Statements must contain the name and capacity in which the witness will appear or. for written comments. the name and capacity of the person submitting the statement. as well as any clients...
210. lappuse - OF URBAN SAFETY NET HOSPITALS Many supporters of various national health reform proposals have suggested that, if reforms were enacted, there would no longer be a need for an institutional health safety net. We can only note that the same thing was said about the enactment of Medicare and Medicaid. Given the strong likelihood that future changes will continue to be incremental and piecemeal, NAPH believes that there will continue to be a strong need for the public health safety net in our nation's...
81. lappuse - Including more than 30 of the country's leading biotechnology companies that discover, develop and produce most of the prescription drugs used In the United States and a substantial portion of the medicines used abroad.
174. lappuse - Committee on Ways and Means, US House of Representatives, announced today that the Subcommittee will hold a hearing on health insurance and the uninsured.
292. lappuse - If I'd known I was going to live this long, I'd have taken better care of myself!
210. lappuse - It must be recognized, in implementing "managed competition", that the playing field is not currently level for either providers or patients in the inner cities and remote rural areas. To be equitable, and to guarantee access for patients in such areas to the broadest range of health and social services, a plan must ensure that all safety net providers (including public hospitals that currently serve a high volume of low income patients...
8. lappuse - I would be happy to take any questions you might have. [The prepared statement of Mr.
176. lappuse - B-318 Rayburn House Office Building. All other details for the hearing remain the same. (See Health Subcommittee press release No.
3. lappuse - Each statement presented for printing to the Committee by witness, any written statement or exhibit submitted for the printed record or any written comments in response to a request for written comments must conform to the guidelines listed below. Any statement or exhibit not in compliance with these guidelines will not be printed, but will be maintained in the Committee files for review and use by the Committee.
82. lappuse - The prices for new products also show a moderating trend. Prices for new products approved and launched during 1991-1992 were on average 14 percent lower than the leading product in the same therapeutic category, according to the BCG study.